Contribute Try STAT+ Today

The biopharma industry is racing to respond to the novel coronavirus pandemic. But the industry has also suffered massive disruptions as shelter-in-place orders have brought some projects screeching to a halt.

A slew of pharmaceutical and biotech companies have suspended their clinical trials in recent weeks. Brian Skorney, a senior biotech research analyst at investment bank Baird, spoke with STAT about how the pandemic has affected the industry and how those disruptions will shape drug development in the months and years to come.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I wish you had asked him about Moderna, or can you give us an update with a biotech analyst next week after Moderna’s presentation

Comments are closed.